ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MLR Maelor

100.00
0.00 (0.00%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maelor LSE:MLR London Ordinary Share GB00B2QBY649 ORD 70P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 100.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

First Day of Dealings

08/05/2007 9:01am

UK Regulatory


RNS Number:1874W
Maelor PLC
08 May 2007

8 May 2007




                     Maelor plc ("Maelor" or the "Company")

               Re-Admission, Conditional Placing and Acquisition



The Board of Maelor plc (AIM: MLR), the specialist critical care company, is
pleased to announce that it has conditionally raised #8 million through a
placing of 80,000,000 new ordinary shares of 10p (the "Placing") by Noble &
Company Limited, Maelor's nominated adviser and broker.


Geoff McMillan, Non-Executive Chairman, Tim Wright, Chief Executive Officer,
Nigel Goldsmith, Finance Director, Ann Hardy, Executive Director and John
Gregory, Non-Executive Director have all participated in the Placing.


First Admission and the commencement of dealings in relation to the 70,005,833
Existing Ordinary Shares and New VCT/EIS Shares will take place today. It is
expected that Second Admission and the commencement of dealings in relation to
the 44,275,000 Protected VCT Shares and Non-VCT Shares will occur at 8am on 9
May 2007 and that Third Admission and commencement of dealings in relation to
10,000,000 Consideration Shares will occur at 8am on 10 May 2007. It is expected
that completion of the acquisition of Acorus Therapeutics Limited will occur
immediately following Third Admission.


Following completion of the acquisition of Acorus Therapeutics Limited, the
Company will have 124,280,833 ordinary shares of 10p in issue.


Tim Wright, CEO of Maelor said:


"The acquisition of Acorus is a transforming transaction for Maelor, creating a
strong, profitable business with positive cash flow.  The integration risks,
costs and distractions are minimal due to the virtual nature of Acorus and the
combined product portfolios offer a high degree of synergy in terms of customer
base and distribution channels. We now have a product portfolio and pipeline
capable of delivering strong future growth."


                                    - Ends -


For further information, call:

Maelor plc
Tim Wright - 01244 625150

Noble & Company Limited
Matthew Hall/Sam Reynolds - 020 7763 2200

Financial Dynamics
Billy Clegg/Edward Westropp - 020 7831 3113


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCUBARRBURVRUR

1 Year Maelor Chart

1 Year Maelor Chart

1 Month Maelor Chart

1 Month Maelor Chart

Your Recent History

Delayed Upgrade Clock